Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review

Boehringer Ingelheim International GmbH - Strategic SWOT Analysis Review


- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.

This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – GlobalData’s summarization of the company’s business strategy.
  • SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Highlights

Boehringer Ingelheim International GmbH (Boehringer), a subsidiary of CH Boehringer Sohn AG & Co KG, is a pharmaceutical company that develops, manufactures and markets pharmaceuticals, parasiticides, vaccines and therapeutics for unmet medical needs. It offers an array of products including human diseases, animal health care products, and biopharmaceuticals. The company’s products are used for the treatment central nervous system disorders, cardiometabolic diseases, respiratory diseases, cancer, immunology, and retinal diseases, among others. It also offers animal healthcare products for swine, ruminant, poultry, horses, and pets, among others. Boehringer is headquartered in Ingelheim am Rhein,Rhineland-Palatinate, Germany.

Boehringer Ingelheim International GmbH Key Recent Developments

Apr 30,2024: FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs
Apr 23,2024: Ochre Bio and Boehringer enter CLD regenerative therapy deal
Apr 16,2024: Boehringer Ingelheim Reports Strong Growth in 2023 and Accelerates Late-Stage Pipeline
Apr 09,2024: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets

Reasons to Buy
  • Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
  • Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
  • Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
  • Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.


Section 1 - About the Company
Boehringer Ingelheim International GmbH - Key Facts
Boehringer Ingelheim International GmbH - Key Employees
Boehringer Ingelheim International GmbH - Key Employee Biographies
Boehringer Ingelheim International GmbH - Major Products and Services
Boehringer Ingelheim International GmbH - History
Boehringer Ingelheim International GmbH - Company Statement
Boehringer Ingelheim International GmbH - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Boehringer Ingelheim International GmbH - Business Description
Business Segment: Animal Health
Overview
Performance
Business Segment: Human Pharmaceuticals
Overview
Performance
Business Segment: Other Sales
Performance
Geographical Segment: Americas
Performance
Geographical Segment: Asia/Australia/Africa
Performance
Geographical Segment: Europe
Performance
R&D Overview
Boehringer Ingelheim International GmbH - Corporate Strategy
Boehringer Ingelheim International GmbH - SWOT Analysis
SWOT Analysis - Overview
Boehringer Ingelheim International GmbH - Strengths
Boehringer Ingelheim International GmbH - Weaknesses
Boehringer Ingelheim International GmbH - Opportunities
Boehringer Ingelheim International GmbH - Threats
Boehringer Ingelheim International GmbH - Key Competitors
Section 3 – Company’s Lifesciences Financial Deals and Alliances
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Boehringer Ingelheim International GmbH, Recent Deals Summary
Section 4 – Company’s Recent Developments
Apr 30, 2024: FTC Expands Patent Listing Challenges, Targeting More Than 300 Junk Listings for Diabetes, Weight Loss, Asthma and COPD Drugs
Apr 23, 2024: Ochre Bio and Boehringer enter CLD regenerative therapy deal
Apr 16, 2024: Boehringer Ingelheim Reports Strong Growth in 2023 and Accelerates Late-Stage Pipeline
Apr 09, 2024: Boehringer Ingelheim Biopharmaceuticals China Receives Approval for Supply of EU and US Markets
Jan 11, 2024: Boehringer expands production site in Greece for new medicine
Jan 03, 2024: Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases
Dec 18, 2023: Boehringer Ingelheim Announces Appointments Board of Managing Directors
Dec 06, 2023: Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
Nov 07, 2023: Boehringer Ingelheim and Ambio Sign Cooperation Development Agreement for Innovative Drugs for Inflammatory Diseases
Oct 30, 2023: Life Forward - Boehringer Ingelheim Unveils Its Evolved Company Brand
Section 5 – Appendix
Methodology
About GlobalData
Contact Us
Disclaimer
List of Tables
Boehringer Ingelheim International GmbH, Key Facts
Boehringer Ingelheim International GmbH, Key Employees
Boehringer Ingelheim International GmbH, Key Employee Biographies
Boehringer Ingelheim International GmbH, Major Products and Services
Boehringer Ingelheim International GmbH, History
Boehringer Ingelheim International GmbH, Subsidiaries
Boehringer Ingelheim International GmbH, Key Competitors
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Type, 2018 to YTD 2024
Boehringer Ingelheim International GmbH, Recent Deals Summary
List of Figures
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2018 to YTD 2024
Boehringer Ingelheim International GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2018 to YTD 2024

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings